Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

Doctors and researchers say ping pong can help slow Parkinson's disease. The South County Recreation Center in Bixby hosts ...

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...

WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's ...

The FDA on Tuesday signed off on Supernus Pharmaceuticals’ apomorphine hydrochloride injection—to be marketed under the brand ...

Semaglutide, the drug used in Ozempic, has been linked to lowering the risk of Alzheimer's disease in the past. So, it was ...

Taryn Robertson, a professor at Randolph College, is currently fundraising and training to run a marathon for her father who ...

Now, a new study from Renmin Hospital of Wuhan University provides strong evidence that kidney failure may also contribute to the development of Parkinson’s disease by triggering the spread of ...

Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.

Traditional deep brain stimulation surgery can take up to 10 hours to complete, with the patient wide awake. This robotic ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers.

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...